CAJ | 학술논문

目的：观察胸腺肽+阿莫西林克拉维酸钾在耐多药肺结核患者治疗中的疗效。方法将我院收集到的69例耐多药的肺结核病人，随机的分为治疗组和对照组，治疗组35例，对照组34例。对照组采取耐多药肺结核标准治疗方案，治疗组在对照组基础上加用胸腺肽+阿莫西林克拉维酸钾。所有患者疗程为24个月。结果治疗组和对照组治愈率分别为82．9%及58．8%，两组比较差异有统计学意义( P<0．05)；两组不良反应无明显统计学差异。结论胸腺肽+阿莫西林克拉维酸钾联合标准抗结核药治疗耐多药肺结核临床疗效明显。
목적：관찰흉선태+아막서림극랍유산갑재내다약폐결핵환자치료중적료효。방법장아원수집도적69례내다약적폐결핵병인，수궤적분위치료조화대조조，치료조35례，대조조34례。대조조채취내다약폐결핵표준치료방안，치료조재대조조기출상가용흉선태+아막서림극랍유산갑。소유환자료정위24개월。결과치료조화대조조치유솔분별위82．9%급58．8%，량조비교차이유통계학의의( P<0．05)；량조불량반응무명현통계학차이。결론흉선태+아막서림극랍유산갑연합표준항결핵약치료내다약폐결핵림상료효명현。
Objective To evaluate the curative effect of thymosin and amoxicillin/clavulanate potassium ( AMC) in the treatment of multi-drug resistant pulmonary tuberculosis ( MDR-PTB) . Methods 69 cases of MDR-PTB patients were randomly divided into the treatment group ( n=35 ) and the control group ( n=34 ) . The control group received the standard treatment, and the treatment group was given thymosin and amoxicillin/clavulanate potas-sium on the basis of the control group. All patients were treated for 24 months. Results The curative rate was 82. 9% and 58. 8% respectively in the treatment group and the control group (P<0. 05). There was no obvious difference in adverse reaction between the two groups. Conclusion Thymosin and amoxicillin/clavulanate potassium have better curative effect than the standard therapy does in the treatment of MDR-PTB patients, which have good safety and tolerance.